Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine. The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen. Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.
Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.
No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.
Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.